Sermorelin, traced

What is sermorelin and how is it used?

Sermorelin is a 29-amino-acid synthetic peptide that corresponds to the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and triggers a discrete, pulsatile release of the body's own growth hormone — it does not contain growth hormone itself ^[13].

The historic FDA-approved indications were two: treatment of idiopathic growth hormone deficiency in children with growth failure, and provocative diagnostic testing of pituitary GH secretory capacity in adults and children ^[1][2]. In current U.S. practice, sermorelin reaches patients exclusively through 503A or 503B compounding pharmacies on the basis of an individual prescription; it is not commercially available as an FDA-approved finished product ^[18].

Is sermorelin still made or available?

Not as an FDA-approved finished drug — the previously approved manufactured product was voluntarily discontinued by its original sponsor in 2008, and FDA marketing approval was withdrawn in 2009 ^[18].

It remains available in the United States through 503A and 503B compounding pharmacies. Sermorelin sits on Category 1 of the FDA's interim 503A Bulks List, meaning the agency has stated it does not currently intend to take enforcement action against pharmacies preparing sermorelin from a bulk substance, pending final Pharmacy Compounding Advisory Committee review ^[18]. A 2024 review of adult GHD diagnostic practice notes that this is why compounded sermorelin is, for many U.S. clinicians, the only practical GHRH-class option that has remained accessible over the past decade ^[14].

Why was the FDA-approved sermorelin product discontinued in 2008?

The 2008 discontinuation was a commercial decision attributed to difficulties in the manufacturing process of the active pharmaceutical ingredient — not a regulatory action and not a response to safety or efficacy findings.

The FDA made this explicit in a Federal Register determination published March 4, 2013 (78 FR 14114). The agency formally found that the product at the three previously approved strengths was not withdrawn from sale for reasons of safety or effectiveness ^[18]. That non-safety, non-efficacy finding is the regulatory anchor that 503A and 503B compounding pharmacies cite when preparing sermorelin under the 'previously FDA-approved' pathway.

What forms of sermorelin are available today?

Subcutaneous injection is by far the most common research and compounded form, supplied as a lyophilized powder requiring reconstitution with bacteriostatic water for injection in research formulations or sterile water in the historic FDA-approved label. Reconstituted solutions are typically refrigerated at 2-8 °C and used within a defined window assigned by the compounding pharmacy. The peptide is sensitive to heat and to repeated freeze-thaw ^[6].

Sublingual and oral troche formulations also appear in some compounded research preparations; bioavailability through these routes is less well characterized in the peer-reviewed literature than the subcutaneous route. Intravenous administration appears in the literature only in the historic diagnostic context (a 1 µg/kg IV bolus for provocative GH stimulation testing) ^[2].

How does sermorelin differ from recombinant growth hormone?

Recombinant human GH (rhGH) is exogenous growth hormone — the hormone itself, delivered into circulation, bypassing the pituitary entirely. Sermorelin is a GHRH analog — a signal upstream of the pituitary, asking the pituitary to release its own GH ^[11].

The practical implication is that sermorelin-driven GH release remains subject to intact somatostatin and IGF-1 negative feedback. Rising IGF-1 still suppresses further GH release; somatostatin tone still opposes GHRH at the somatotroph. Output is self-limiting. Exogenous rhGH has no such feedback because it bypasses the receptor that the feedback acts on. The 2025 Frontiers in Aging clinical review names this preserved pulsatility as a mechanistically distinct safety paradigm for GHRH-analog research versus continuous rhGH replacement ^[15][11].

What is the half-life of sermorelin?

Approximately 11-12 minutes, after either intravenous or subcutaneous administration. Plasma clearance in adults is approximately 2.4-2.8 L/min ^[6].

The short half-life is the design intent. The molecule is meant to produce a discrete physiologic GH pulse, not sustained receptor stimulation. Endogenous GHRH signals the pituitary in bursts, not a steady drip, and sermorelin's pharmacokinetics mimic that pattern.

It is also the reason that structurally stabilized analogs exist. CJC-1295 (no DAC) substitutes amino acids in the GHRH(1-29) sequence to resist DPP-IV degradation; tesamorelin is a separately stabilized analog. Both extend functional half-life beyond sermorelin's. Sermorelin remains the canonical molecule where strict mimicry of endogenous GHRH pharmacokinetics is the design intent.

What does the research say about sermorelin in children and in older adults?

In children with idiopathic growth hormone deficiency, the pivotal international multicenter trial reported mean height velocity rising from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months on the labeled 30 µg/kg subcutaneous nightly regimen; 74% were classified as good responders at six months ^[1]. A contemporary review confirmed sustained catch-up growth through twelve months in the majority of treated children ^[2]. A separate trial in children with idiopathic short stature without classical GHD also reported a sustained increase in growth velocity ^[5].

In older adults, twice-daily 1 mg subcutaneous GHRH(1-29) restored 24-hour GH and IGF-1 in healthy men aged 60-78 to values not significantly different from young controls ^[3]. Sixteen weeks of nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg in adults 55-71 increased lean body mass by about 1.26 kg in men, improved insulin sensitivity in men, and increased skin thickness in both sexes ^[4]. Twenty weeks of nightly GHRH-analog dosing in adults 55-87 significantly improved executive function (p = .005) and decreased body fat 7.4% in the Baker 2012 trial ^[7], with companion neurochemical and exosome-biomarker findings consistent with the cognitive improvement ^[8][17].

Why is sermorelin often paired with ipamorelin in research?

The two compounds act on different receptors that converge on the same somatotroph cell. Sermorelin is a GHRH receptor agonist; ipamorelin is a ghrelin/GHS-R1a receptor agonist. The two receptor systems use independent intracellular pathways, and combined GHRH + GHS administration produces synergistic GH release that exceeds the additive sum of either compound alone ^[16].

A 2020 review of growth hormone secretagogues consolidates the mechanistic distinction between the two classes and reviews the synergy evidence. Sermorelin and ipamorelin together cover both arms of the somatotroph's regulatory input — which is the pharmacologic basis for the common compounded co-administration pattern in research literature ^[16].

Is sermorelin safe? What does the historical safety record show?

The FDA-era pediatric trial record characterizes sermorelin's safety profile as mild and stereotyped. The most common treatment-related adverse event was a transient injection-site reaction — pain, swelling, or redness — in approximately 1 of 6 pediatric patients. Other events reported at individual rates below 1% included headache, facial flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed over the trial period ^[10].

The historic label listed two principal contraindications: active malignancy and unevaluated pituitary mass. Long-term elevation of IGF-1 has been associated in epidemiologic studies with theoretical increases in malignancy risk; causality remains debated, and most research protocols monitor IGF-1 and target the upper-normal age range ^[11].

Is sermorelin banned by WADA?

Yes. GHRH and GHRH-mimetic peptides — including sermorelin — are classified as Prohibited Substances under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the World Anti-Doping Agency (WADA) Prohibited List, prohibited both in-competition and out-of-competition.

Athletes subject to anti-doping rules should treat the WADA classification as definitive. Even a therapeutic-use exemption pathway for an FDA-approved indication would be governed by the relevant federation's anti-doping authority, not by the compounding pharmacy or the prescribing clinician.

How is sermorelin regulated by the FDA in 2026?

Sermorelin's regulatory state in 2026 is layered:

1. No FDA-approved finished product on the market. The 1997 FDA-approved sermorelin acetate injection (NDA 020443) was voluntarily discontinued by its manufacturer in 2008, and FDA marketing approval was withdrawn in 2009 ^[18].
2. Federal Register determination of non-safety, non-efficacy basis for withdrawal. The March 4, 2013 determination (78 FR 14114) formally established that the prior approved product at 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp was not withdrawn from sale for reasons of safety or effectiveness ^[18].
3. 503A Bulks List Category 1. Sermorelin appears on Category 1 of the FDA's interim 503A Bulks List, indicating that the agency does not currently intend to take enforcement action against compounders preparing sermorelin from a bulk substance, pending final Pharmacy Compounding Advisory Committee review.

All U.S. patient access in 2026 is via 503A or 503B compounding pharmacies on the basis of an individual patient prescription. None of this is medical, regulatory, or legal advice; clinicians and pharmacists rely on current professional and regulatory sources, not on this site.

How does sermorelin compare to CJC-1295?

Same mechanism, different pharmacokinetics. CJC-1295 (no DAC) — sometimes called Modified GRF 1-29 — is structurally a stabilized variant of the sermorelin GHRH(1-29) sequence with amino-acid substitutions that resist degradation by the enzyme DPP-IV. The receptor activity is the same GHRH-R agonist mechanism; the practical difference is a longer functional half-life ^[16].

Which molecule is preferable in a given research protocol depends on whether the design calls for strict pulsatile mimicry of endogenous GHRH signaling (sermorelin) or for extended GHRH-R stimulation (CJC-1295). Both remain investigational research peptides; neither is currently an FDA-approved finished product.

Does this site sell sermorelin?

No. This is an editorial reading room for the published research literature on sermorelin and the GHRH-R agonist class. The site does not sell, distribute, manufacture, or dispense any product. It is not affiliated with any compounding pharmacy, manufacturer, or vendor. It does not employ clinicians and it does not provide medical advice.